Actelion Pharmaceuticals Ltd is a biopharmaceutical company headquartered in Allschwil/Basel, Switzerland, focusing on the discovery, development and commercialization of innovative treatments to serve high unmet medical needs.
We strive to communicate transparently, based on fact and with consistency. In line with our traditional communication channels, we utilize and leverage our Facebook channel to create awareness for rare diseases, bring our Corporate Sustainability activities into focus or just create excitement for science. Facebook allows us to share a more personal view of us and our company culture. Please read our community guidelines on https://www.actelion.com/documents/corporate/policies-charters/facebook-guidelines.pdf or visit our website www.actelion.com
We strive to communicate transparently, based on fact and with consistency. In line with our traditional communication channels, we utilize and leverage our Facebook channel to create awareness for rare diseases, bring our Corporate Sustainability activities into focus or just create excitement for science. Facebook allows us to share a more personal view of us and our company culture. Please read our community guidelines on https://www.actelion.com/documents/corporate/policies-charters/facebook-guidelines.pdf or visit our website www.actelion.com
Location: Switzerland, Basel-Country, Allschwil
Phone: +41 61 565 65 65
Investors 5
| Date | Name | Website |
| - | Sofinnova ... | sofinnovap... |
| - | NeoMed Man... | neomed.net... |
| - | Sofinnova ... | sofinnova.... |
| - | Wellington... | wellington... |
| - | CITA Inves... | cita-inves... |
Mentions in press and media 5
| Date | Title | Description |
| 05.08.2024 | Vanda Pharmaceuticals: Navigating Challenges and Opportunities in the Biopharmaceutical Landscape | Vanda Pharmaceuticals is at a crossroads. The company recently reported its second-quarter financial results for 2024, revealing a mix of growth and challenges. With revenues of $50.5 million, Vanda saw a 6% increase from the previous quart... |
| 31.07.2024 | Vanda Pharmaceuticals Reports Second Quarter 2024 Financial Results | Revenues for Q2 2024 were $50.5 million, an increase of 6% compared to Q1 2024 and an increase of 10% compared to Q2 2023 Financial Guidance reinstated for Full Year 2024 Fanapt® approved for the acute treatment of bipolar I disorder; comme... |
| 28.07.2022 | Pulmonary Arterial Hypertension Market to Reach the Value of US$ 13.5 Bn by 2028 | TMR Image Pulmonary Arterial Hypertension (PAH) Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028 WILMINGTON, DELAWARE, USA, July 28, 2022 /EINPresswire.com/ -- According to Transparency Market Research... |
| 26.01.2017 | Term Sheet — Thursday, January 26 | BIG, BRAZEN M&A PE vs. Corporate: If yesterday’s last-minute buyout of AppDynamics is any indication, 2017 could be less about the return of big IPOs and more about the continuation of big, brazen M&A. That’s bad news for IPO banker... |
| 26.06.2015 | Actelion creates new start-up |